All News
Stop repeating the #ANA test!
46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
TheDaoIndex KDAO2011 ( View Tweet)
Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy.
@RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR
Julian Segan JulianSegan ( View Tweet)
Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Advancing Telemedicine in Rheumatology
'60% prefer telemedicine for routine visits and review lab results'
https://t.co/HUgoocXodE
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
Tofa 5 mg BID successful in treating refractory uveitis in reducing inflammation and reducing steroid dosage. Abs 1041 #ACR22 @RheumNow https://t.co/dtAEhW7dEG https://t.co/Xbw2iEsYHh
Dr. Rachel Tate uptoTate ( View Tweet)
#abs0948 #acr22 @rheumnow perception on fertility&ART in pts w/rheum Dx: 60% believe their Dx affects fertility/25% believe meds do: most cited MTX, steroids, TNFi, HCQ, NSAIDs. 92% heard of ART but unsure if safe or successful w/their Dx. Hx of infertility 29%/only 52% go w/ART https://t.co/lmaM773gP5
Olga Petryna DrPetryna ( View Tweet)
There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID
David Liew drdavidliew ( View Tweet)
Did you know?
Teratogens may take the form of:
✳️Drugs & chemicals
✳️Physical agents
✳️Infections
✳️Metabolic conditions
#ACR22 @Rheumnow #MedTwitter https://t.co/GfHL28RYjm
sheila RHEUMarampa ( View Tweet)
USA vs Canada
It's kicking off
and a super hot topic
The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis
Holers/Deane (treat 🇺🇸)
El Gabalawy/Pope (don't treat 🇨🇦)
What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf
David Liew drdavidliew ( View Tweet)
Terrier @TerrierBen et al Mepolizumab in vasculitic type EGPA in MIRRA. Vasculitic features similar in patients who did/did not achieve remission. Decreased flares of all type, including vasculitic. @RheumNow #ACR22 Abstr#1075 https://t.co/0MkJvnCnf1 https://t.co/ZxbDqlvgae
Richard Conway RichardPAConway ( View Tweet)
Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater kidney improvement (SELENA-SLEDAI), less kidney worsening (BILAG), and improved eGFR. Abs 0352 #ACR22 @RheumNow https://t.co/w50uEYVDup https://t.co/JyKZEZG6DZ
Dr. Rachel Tate uptoTate ( View Tweet)
Bekker et al. Safety of avacopan across 3 trials. Rates of AEs, SAEs, infection all lower in avacopan group. @RheumNow #ACR22 Abstr#1077 https://t.co/n4zhC2zf8k https://t.co/Q8raSEERah
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr# Interesting data for IMID patients who had #COVID. A cohort study in Norway (1/3 had RA and mostly on TNFi; 6% RTX) showed greater anti-Spike Ab in 4th vaccine vs 3rd dose. However, the greatest was in those with 3 x doses + COVID infection (Hybrid) @RheumNow https://t.co/hGFSGqJtBT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Benavides-Villanueva et al. Single centre 28 case series of IVIG in AAV. Used due to relapse in 25, concomitant infection in 3. BVAS 0 in 56.5% at month 24, glucocorticoid sparing effect. @RheumNow #ACR22 Abstr#1079 https://t.co/wfg1HSKM9O https://t.co/DuReVU2jA4
Richard Conway RichardPAConway ( View Tweet)
Abs 0714 at #ACR22 real-world obs study finds seropositive and seronegative RA patients had similar clinical effectiveness 1 year after starting bDMARD or JAKi. @RheumNow https://t.co/UrVgZ0zVno https://t.co/LnXMfOkQIp
Dr. Rachel Tate uptoTate ( View Tweet)
Early TNFi use and cardiovascular events in AS
Abstract #0415 #ACR22 @RheumNow
📍17.6k patients, 91% male, 80% white
📍TNFi initiators were younger with lower prev. of HTN and DM
📍TNFi was associated with higher risk of incident CVD, CVA, and MACE https://t.co/7bCkfk7EYY
Catherine Sims, MD DrCassySims ( View Tweet)
I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence!
Receiving less HCQ = more damage and more CVD
Observational, not clearly causal, but should make you wonder...
Are we sure we should be shooting for <5mg/kg/day?
#ACR22 @RheumNow #0982 https://t.co/SuAwSumgu1
Mike Putman EBRheum ( View Tweet)
Abs 0698 at #ACR22 finds that a 20 pack-year or more of cigarette smoking assoc'd w/ a modestly higher risk of incident PMR among women. Yet another reason to encourage smoking cessation in patients. @RheumNow https://t.co/HOVTIPSjOi https://t.co/Akuukxb90Q
Dr. Rachel Tate uptoTate ( View Tweet)
Nettleton @SattuiSEMD @zach_wallace_md @EBRheum et al. PJP prophylaxis in AAV. Incidence PJP 15.9/1000PY. 5/8 who got PJP got prophylaxis. Prophylaxis assoc medication-related adverse events. @RheumNow #ACR22 Abstr#1081 https://t.co/kAD1nRSdPa https://t.co/HjqtW1P6N4
Richard Conway RichardPAConway ( View Tweet)
Banik et al. MTX as induction and maintenance for localised GPA. 48% in remission at 1 year. 39% required RTX. @RheumNow #ACR22 Abstr#1082 https://t.co/Pn8owLgaTj https://t.co/0iEeNuY2JU
Richard Conway RichardPAConway ( View Tweet)